HOME > ACADEMIA
ACADEMIA
- National Geriatrics Center to Kick Off Leqembi Treatment on Feb. 13
January 25, 2024
- NCC Launches Investigator-Led Studies on 5 Unapproved, Off-Label Drugs for Pediatric, AYA Cancers
January 22, 2024
- Expert Charts Future of Alzheimer’s Treatment with More Drugs in Wings to Follow Leqembi
January 22, 2024
- Medical Interns Improperly Prescribe, Use GLP-1 Agent for Off-Label Purpose
December 18, 2023
- Japan Obesity Society Urges Attention to Suicidal Thoughts in Patients Who Use Wegovy
November 29, 2023
- Scientific Societies Urge Greater Caution for COVID Drug Use in Women of Childbearing Age
November 15, 2023
- Chemotherapy Society Urges Govt to Create Body to Spur Drug Discovery
October 31, 2023
- G1 Product Info Could Disappear after Withdrawal, PMDA Website Should Retain Posting: Pharmacist
October 11, 2023
- Flu Drug Spending Hits 48 Billion Yen in FY2017, NCGM Flags Cost-Effectiveness
October 10, 2023
- NCC Announces “No Placebo Initiative” for Cancer Trials
October 10, 2023
- Academic Society Condemns Off-Label Use of GLP-1 Diabetes Drugs as Shipment Curbs Persist
September 25, 2023
- Japan Society to Select Facilities to Use Luxturna; 10 Sites for Genetic Testing, 2 or 3 for Treatment
August 25, 2023
- Ultra-High Cost of Luxturna Would Be Offset by Its Clinical Significance, Have Limited Financial Impact: Expert
August 25, 2023
- NIID Researcher Contracts Typhoid Fever
August 21, 2023
- Thai Patients to Join NCC Clinical Studies in “World’s First” Cross-Border DCT Deal
June 29, 2023
- CGP Assays Prior to Initial Treatment Would Have Little Impact on Health Finances: Professor
May 31, 2023
- Keep Public Funding for COVID Drugs to Get through This Winter: Academic Societies
May 25, 2023
- OB/GYN Society Aims for Early Use of Oral Abortion Pill at Clinics without Beds
May 12, 2023
- Lung Cancer Trial Aborted as 11 Die after Opdivo-Yervoy Therapy: NCC, JCOG
May 1, 2023
- More Japan-Specific Data, Stable Supplies of Pfizer’s Stelues Needed amid Syphilis Surge: Specialist
April 27, 2023
ページ
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
